BP control rates are suboptimal in many countries. However, in clinical trials, more than 70 % of hypertensive patients are able to achieve BP control. In addition, data from France and North America (CHEP and NHANES) show more than 50 % of the general hypertensive population can achieve BP control. The French and Italian Societies of Hypertension both have independent initiatives to improve BP control in treated patients.
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The patient cases presented previously demonstrate the need to undertake full clinical assessment of patients with HTN in general practice and highlight the utility of out-ofoffice assessments, such as ABPM and home BP monitoring. They also clearly show that single-pill FDCs have an important role in managing hypertensive patients and improving treatment compliance.
A platform tool allows selection of the appropriate single-pill combination therapy for a variety of patient types. High rates of BP control can be achieved across a range of patients by combining OLM with AML and HCTZ. Increasing the dose of a single drug has proven ineffective; adding a second drug is much more useful.
The frequency of true TRH is much lower than generally believed (as low as 2-3 % of all HTN patients) and the majority of patients can be effectively managed with pharmacotherapy.
